Breaking News Instant updates and real-time market news.

NEOS

Neos Therapeutics

$2.21

-0.05 (-2.21%)

11:41
11/14/18
11/14
11:41
11/14/18
11:41

Neos Therapeutics price target lowered to $6 from $11 at Wells Fargo

Wells Fargo analyst David Maris lowered his price target for Neos Therapeutics to $6 from $11 after the company's Q3 sales last week missed his estimate. The analyst, who admits net pricing continues to be an overall headwind, points out that Neos management turned down a public $10.25 per share offer from another drug company approximately a year ago. Over time, the company's valuation will be realized with better commercial execution, Maris tells investors in a research note. He keeps an Outperform rating on Neos Therapeutics.

NEOS Neos Therapeutics
$2.21

-0.05 (-2.21%)

11/14/17
WELS
11/14/17
NO CHANGE
Target $12
WELS
Outperform
Pfizer ADHD drug supply shortage is positive for Neos, says Wells Fargo
Wells Fargo analyst David Maris says Pfizer (PFE) has sent a letter on physicians dated November 8th telling them of a supply shortage for its liquid and chewable methylphenidate ADHD products. Maris says Pfizer's product is a direct competitor of Neos' (NEOS) recently-launched Cotempla XR-ODT, adding Neos will benefit from having its primary competition in the alternative dose market facing a shortage. The analyst says Cotempla XR-ODT, launched in September, is off to a very strong start, keeping his Outperform rating with a $12 price target on Neos.
01/30/18
BMOC
01/30/18
DOWNGRADE
Target $12
BMOC
Market Perform
Neos Therapeutics downgraded to Market Perform from Outperform at BMO Capital
BMO Capital analyst Gary Nachman downgraded Neos Therapeutics to Market Perform and lowered his price target for the shares to $12 from $14. The analyst views the stock's risk/reward as "appropriately balanced" following the rally over the last year. Nachman is also more cautious on the company's terminal value and would like to see additional pipeline advancements.
03/16/18
WELS
03/16/18
NO CHANGE
Target $14
WELS
Outperform
Neos Therapeutics continues to perform well, says Wells Fargo
Wells Fargo analyst David Maris says Neos Therapeutics is performing well and on an upward trajectory following its Q4 results. The analyst likes the progress the company is making and keeps an Outperform rating on the shares with a $14 price target.
04/24/18
EAMC
04/24/18
INITIATION
Target $15
EAMC
Buy
Neos Therapeutics initiated with a Buy at Empire
Empire initiated Neos Therapeutics with a Buy and $15 price target.

TODAY'S FREE FLY STORIES

PDD

Pinduoduo

$30.14

4.165 (16.04%)

08:00
08/22/19
08/22
08:00
08/22/19
08:00
Options
Pinduoduo call buyer realizes 21% same-day gains »

Notable profits for the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

08:00
08/22/19
08/22
08:00
08/22/19
08:00
General news
Treasury Market Outlook: yields are higher »

Treasury Market Outlook:…

AFL

Aflac

$48.98

-2.88 (-5.55%)

07:59
08/22/19
08/22
07:59
08/22/19
07:59
Hot Stocks
Aflac says 'rigorous, voluntary review' of postal channel sales began in July »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

07:53
08/22/19
08/22
07:53
08/22/19
07:53
Conference/Events
Citigroup to hold a forum »

Citi-REITAS-SGX C-Suite…

JEC

Jacobs Engineering

$86.06

2.45 (2.93%)

07:51
08/22/19
08/22
07:51
08/22/19
07:51
Hot Stocks
Jacobs Engineering appointed as smart meter specialist in Singapore »

Jacobs has been appointed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MSGN

MSG Networks

$14.78

-2.07 (-12.28%)

07:51
08/22/19
08/22
07:51
08/22/19
07:51
Recommendations
MSG Networks analyst commentary  »

MSG Networks price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CERN

Cerner

$71.77

0.44 (0.62%)

07:50
08/22/19
08/22
07:50
08/22/19
07:50
Upgrade
Cerner rating change  »

Cerner upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Sep

  • 09

    Sep

ADMA

ADMA Biologics

$4.05

-0.01 (-0.25%)

07:50
08/22/19
08/22
07:50
08/22/19
07:50
Hot Stocks
ADMA Biologics announces commercial relaunch of BIVIGAM »

ADMA Biologics announces…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Aug

FLWS

1-800-Flowers.com

$19.36

0.74 (3.97%)

07:48
08/22/19
08/22
07:48
08/22/19
07:48
Earnings
1-800-Flowers.com sees FY20 EPS up 8%-10% »

Sees FY20 revenue up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

  • 25

    Sep

FLWS

1-800-Flowers.com

$19.36

0.74 (3.97%)

07:48
08/22/19
08/22
07:48
08/22/19
07:48
Earnings
1-800-Flowers.com reports Q4 adj. EPS (12c), consensus (14c) »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

  • 25

    Sep

SQM

SQM

$25.40

-0.86 (-3.27%)

07:45
08/22/19
08/22
07:45
08/22/19
07:45
Downgrade
SQM rating change  »

SQM downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

  • 10

    Sep

SEDG

SolarEdge

$87.87

3.16 (3.73%)

07:44
08/22/19
08/22
07:44
08/22/19
07:44
Downgrade
SolarEdge rating change  »

SolarEdge downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TIF

Tiffany

$84.51

2.27 (2.76%)

07:43
08/22/19
08/22
07:43
08/22/19
07:43
Recommendations
Tiffany analyst commentary  »

Tiffany price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Aug

DKS

Dick's Sporting

$32.97

0.62 (1.92%)

07:42
08/22/19
08/22
07:42
08/22/19
07:42
Hot Stocks
Dick's Sporting reports Q2 eCommerce sales up 21% »

eCommerce penetration for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

FLR

Fluor

$17.35

0.3 (1.76%)

07:41
08/22/19
08/22
07:41
08/22/19
07:41
Upgrade
Fluor rating change  »

Fluor upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DKS

Dick's Sporting

$32.97

0.62 (1.92%)

07:40
08/22/19
08/22
07:40
08/22/19
07:40
Hot Stocks
Dick's Sporting up 10% after Q2 results beat estimates, FY19 profit view raised »

In pre-market trading,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

PDD

Pinduoduo

$30.14

4.165 (16.04%)

07:39
08/22/19
08/22
07:39
08/22/19
07:39
Recommendations
Pinduoduo analyst commentary  »

Pinduoduo price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DKS

Dick's Sporting

$32.97

0.62 (1.92%)

07:38
08/22/19
08/22
07:38
08/22/19
07:38
Earnings
Dick's Sporting says FY19 EPS guidance includes expected tariff impacts »

The company's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

TGT

Target

$103.11

17.54 (20.50%)

07:36
08/22/19
08/22
07:36
08/22/19
07:36
Recommendations
Target analyst commentary  »

Target valuation remains…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Sep

  • 19

    Sep

  • 25

    Sep

DKS

Dick's Sporting

$32.97

0.62 (1.92%)

07:36
08/22/19
08/22
07:36
08/22/19
07:36
Hot Stocks
Dick's Sporting CEO says 'we are very pleased with our second quarter results' »

"We are very pleased…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

HMSY

HMS Holdings

$38.69

-0.19 (-0.49%)

07:36
08/22/19
08/22
07:36
08/22/19
07:36
Downgrade
HMS Holdings rating change  »

HMS Holdings downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Sep

DKS

Dick's Sporting

$32.97

0.62 (1.92%)

07:35
08/22/19
08/22
07:35
08/22/19
07:35
Hot Stocks
Dick's Sporting sees FY19 CapEx approximately $230M on gross basis »

In 2019, the company…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

CLSD

Clearside Biomedical

$1.27

0.09 (7.66%)

07:35
08/22/19
08/22
07:35
08/22/19
07:35
Hot Stocks
Breaking Hot Stocks news story on Clearside Biomedical »

Clearside Biomedical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

DKS

Dick's Sporting

$32.97

0.62 (1.92%)

07:34
08/22/19
08/22
07:34
08/22/19
07:34
Hot Stocks
Dick's Sporting says continuing strategic review of hunt business »

The company is continuing…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

DKS

Dick's Sporting

$32.97

0.62 (1.92%)

07:33
08/22/19
08/22
07:33
08/22/19
07:33
Hot Stocks
Dick's Sporting sees FY19 SSS growth in 'low single-digits' »

Consolidated same store…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.